Dr. Reddys Laboratories is currently trading at Rs. 4783.80, up by 152.25 points or 3.29% from its previous closing of Rs. 4631.55 on the BSE.
The scrip opened at Rs. 4700.00 and has touched a high and low of Rs. 4783.90 and Rs. 4657.20 respectively. So far 147104 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4,783.90 on 17-Sep-2020 and a 52 week low of Rs. 2497.60 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 4783.90 and Rs. 4336.85 respectively. The current market cap of the company is Rs. 78854.74 crore.
The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.
Dr. Reddy's Laboratories, along with its subsidiaries have launched over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalents of Pataday Once Daily Relief and Pataday Twice Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.
This launch marks the entry of Dr. Reddy’s into the OTC eye care space, and is a testament to deep capabilities in bringing store-brand equivalents of Rx-to-OTC switches to the U.S. market. The Pataday brand had U.S. sales of approximately $31 million since the launch in March 2020.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.